Evidence map›Paper›PMID 39297019›Full record

ArticleBone reports2024

Delineating the relationship between circulating osteoprotegerin and bone health in women with a pathogenic variant in

Aghaghia Mokhber, Elizabeth Hall, Aleksandra Uzelac, Leonardo Salmena, Angela Cheung, Jan Lubinski, Steven A Narod, Joanne Kotsopoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aghaghia MokhberWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Elizabeth HallTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Aleksandra UzelacTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Leonardo SalmenaDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Angela CheungOsteoporosis Program, University Health Network, Centre of Excellence in Skeletal Health Assessment, University of Toronto, Toronto, ON, Canada.
Jan LubinskiPomeranian Medical Institution, Szczecin, Poland.
Steven A NarodWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Joanne KotsopoulosWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Osteoprotegerin (OPG) plays an important role in the inhibition of osteoclast formation and bone resorption. Studies have reported lower OPG levels among women with a pathogenic variant (mutation) in the Methods: Women with a blood sample and clinical data were included in this analysis. An enzyme-linked immunosorbent assay (ELISA) was used to quantify serum OPG (pg/mL) and the 10-year risk of Results: Among 701 women with a Conclusion: Our findings suggest that women with inherently lower OPG may be at risk of lower BMD, the gold standard marker of bone disease. Due to the young age of our cohort, on-going studies are warranted to re-evaluate the association between OPG and FRAX in

Indexed as

Bone mineral densityBRCA mutation carriersFRAXOsteoprotegerin (OPG)

Identifiers

PMID39297019
PMCPMC11408939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.